JP2023528341A5 - - Google Patents
Info
- Publication number
- JP2023528341A5 JP2023528341A5 JP2022572558A JP2022572558A JP2023528341A5 JP 2023528341 A5 JP2023528341 A5 JP 2023528341A5 JP 2022572558 A JP2022572558 A JP 2022572558A JP 2022572558 A JP2022572558 A JP 2022572558A JP 2023528341 A5 JP2023528341 A5 JP 2023528341A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- administered
- fusion polypeptide
- domain variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063033074P | 2020-06-01 | 2020-06-01 | |
| US63/033,074 | 2020-06-01 | ||
| US202063106285P | 2020-10-27 | 2020-10-27 | |
| US63/106,285 | 2020-10-27 | ||
| US202063109083P | 2020-11-03 | 2020-11-03 | |
| US63/109,083 | 2020-11-03 | ||
| US202063114959P | 2020-11-17 | 2020-11-17 | |
| US63/114,959 | 2020-11-17 | ||
| US202163145925P | 2021-02-04 | 2021-02-04 | |
| US63/145,925 | 2021-02-04 | ||
| PCT/US2021/034967 WO2021247430A1 (en) | 2020-06-01 | 2021-05-28 | Combination therapies comprising a hypomethylation agent for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528341A JP2023528341A (ja) | 2023-07-04 |
| JP2023528341A5 true JP2023528341A5 (cg-RX-API-DMAC10.html) | 2024-06-04 |
Family
ID=76808133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022572558A Pending JP2023528341A (ja) | 2020-06-01 | 2021-05-28 | 低メチル化剤を含むがんを治療するための併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12343377B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4157315A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023528341A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230018475A (cg-RX-API-DMAC10.html) |
| CN (1) | CN115666620A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021283083A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3178157A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL298644A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2022014784A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021247430A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106146670B (zh) * | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术(上海)有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| CA3141130A1 (en) * | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
| WO2021108693A1 (en) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
| JP2023528341A (ja) | 2020-06-01 | 2023-07-04 | エーエルエックス オンコロジー インコーポレイテッド | 低メチル化剤を含むがんを治療するための併用療法 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3766511A1 (en) | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | High affinity sirp-alpha reagents |
| ME03550B (me) | 2012-12-17 | 2020-07-20 | Trillium Therapeutics Inc | Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama |
| WO2016023040A1 (en) | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| CN106146670B (zh) | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术(上海)有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| DK3298043T3 (da) | 2015-05-18 | 2021-02-15 | Ab Initio Biotherapeutics Inc | SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse |
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| DK4186927T3 (da) | 2015-10-21 | 2025-06-10 | Ose Immunotherapeutics | Fremgangsmåder og sammensætninger til at ændre makrofagers polarisering til pro-inflammatoriske celler til behandling af kræft |
| WO2017177333A1 (en) | 2016-04-15 | 2017-10-19 | Trillium Therapeutics Inc. | Macrophage stimulation in cd47 blockade therapy |
| EP3493845A4 (en) | 2016-08-03 | 2020-04-15 | The Board of Trustees of the Leland Stanford Junior University | INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| CA3042581A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| WO2018081898A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| CN110325549B (zh) | 2016-12-09 | 2024-03-08 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| PT3443010T (pt) | 2017-02-17 | 2024-10-21 | Ose Immunotherapeutics | Novos anticorpos anti-sirpa e suas aplicações terapêuticas |
| CN110300764A (zh) | 2017-02-17 | 2019-10-01 | Ose免疫疗法 | 抗SIRPg抗体的新用途 |
| CA3057718A1 (en) | 2017-03-28 | 2018-10-04 | Trillium Therapeutics Inc. | Cd47 blockade therapy |
| JP7160833B2 (ja) | 2017-04-13 | 2022-10-25 | サイロパ ビー.ブイ. | 抗sirpアルファ抗体 |
| PT3625259T (pt) | 2017-05-16 | 2024-07-04 | Synthon Biopharmaceuticals Bv | Anticorpos anti-sirpalfa |
| EP3658589B1 (en) | 2017-07-26 | 2023-09-27 | Forty Seven, Inc. | Anti-sirp-alpha antibodies and related methods |
| JP2021534769A (ja) | 2018-08-31 | 2021-12-16 | エーエルエックス オンコロジー インコーポレイテッド | デコイポリペプチド |
| CA3141130A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
| EP3980747A1 (en) | 2019-06-07 | 2022-04-13 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| PH12022550835A1 (en) | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| WO2021108693A1 (en) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
| JP2023528341A (ja) | 2020-06-01 | 2023-07-04 | エーエルエックス オンコロジー インコーポレイテッド | 低メチル化剤を含むがんを治療するための併用療法 |
| WO2022010806A1 (en) | 2020-07-06 | 2022-01-13 | ALX Oncology Inc. | Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays |
| WO2022120286A1 (en) | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
-
2021
- 2021-05-28 JP JP2022572558A patent/JP2023528341A/ja active Pending
- 2021-05-28 EP EP21739202.6A patent/EP4157315A1/en active Pending
- 2021-05-28 US US17/334,151 patent/US12343377B2/en active Active
- 2021-05-28 AU AU2021283083A patent/AU2021283083A1/en not_active Abandoned
- 2021-05-28 CA CA3178157A patent/CA3178157A1/en active Pending
- 2021-05-28 WO PCT/US2021/034967 patent/WO2021247430A1/en not_active Ceased
- 2021-05-28 IL IL298644A patent/IL298644A/en unknown
- 2021-05-28 KR KR1020227046227A patent/KR20230018475A/ko not_active Withdrawn
- 2021-05-28 MX MX2022014784A patent/MX2022014784A/es unknown
- 2021-05-28 CN CN202180039242.XA patent/CN115666620A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023503943A5 (cg-RX-API-DMAC10.html) | ||
| US12377144B2 (en) | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen | |
| JP2019530434A5 (cg-RX-API-DMAC10.html) | ||
| JP7729778B2 (ja) | Fms様チロシンキナーゼ3(flt3)に対するキメラタンパク質およびキメラタンパク質複合体 | |
| US20230416402A1 (en) | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2 | |
| CN101868478B (zh) | 巨噬细胞刺激蛋白质受体(ron)的抑制及其治疗方法 | |
| US20240076355A1 (en) | Interferon Prodrugs and Methods of Making and Using the Same | |
| JP2002514405A5 (cg-RX-API-DMAC10.html) | ||
| CA3173919A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| PT771216E (pt) | Metodos e composicoes para a coagulacao especifica da vasculatura tumoral | |
| CN106536562A (zh) | 来那度胺或泊利度胺与经抗CD38抗体灭毒的干扰素α构筑体的组合,和其用途 | |
| JP2007500236A5 (cg-RX-API-DMAC10.html) | ||
| TW201023855A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan | |
| IL292780A (en) | A new 4-1bbl trimer containing antigen-binding molecules | |
| JP2024520902A5 (cg-RX-API-DMAC10.html) | ||
| JP2019524713A5 (cg-RX-API-DMAC10.html) | ||
| TW202330040A (zh) | 抗her2抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2022513421A5 (cg-RX-API-DMAC10.html) | ||
| JP2025523369A5 (cg-RX-API-DMAC10.html) | ||
| KR20230018475A (ko) | 암 치료용 저메틸화제를 포함하는 병용 요법 | |
| JP2015529656A5 (cg-RX-API-DMAC10.html) | ||
| CN111936170A (zh) | 降低抗cd30抗体药物缀合物疗法的副作用的方法 | |
| US20220185857A1 (en) | Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins | |
| CN112996540B (zh) | 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途 | |
| JP2025511002A (ja) | 活性化可能な二重特異性抗cd3および抗pd-l1タンパク質ならびにその使用 |